GSK3beta

PfGSK-3beta (PF3D7_0312400) is a catalytically active serine/threonine kinase of Plasmodium falciparum that couples protein phosphorylation to the parasite's erythrocytic and sexual development (PMID:15023360, PMID:35961464). Recombinant enzyme phosphorylates GSK-3-specific peptide substrates, glycogen synthase, and tau, establishing its intrinsic kinase activity and substrate range (PMID:15023360). Functionally, it acts within an invasion-associated phosphorylation hierarchy: it phosphorylates threonine 613 in the cytoplasmic domain of the invasion ligand AMA1, but only after PKA-mediated priming at S610, and both steps are required for efficient erythrocyte invasion (PMID:27698395). Its own activity is positively regulated by autophosphorylation of an unconventional N-terminal extension, which induces activating conformational changes detected by SAXS (PMID:35023554). The enzyme is predominantly expressed at the early trophozoite stage and is exported to the erythrocyte cytoplasm where it associates with vesicle-like structures (PMID:15023360). Genetically, PfGSK-3beta is dispensable for asexual blood-stage proliferation but its disruption reduces erythrocyte invasion by ~69% (PMID:35961464), while conditional inactivation causes malformed gametocytes and death in late gametocytogenesis, making it essential for gametocyte maturation (PMID:35961464). It is pharmacologically distinguishable from human GSK-3beta through subtle ATP-pocket differences that permit selective inhibitors (PMID:15023360, PMID:23214499), and unlike mammalian GSK-3beta it does not bind axin (PMID:15023360).

1. 2004 High

   Establishing that the parasite gene encodes a functional kinase was the first requirement; in vitro assays showed PfGSK-3beta phosphorylates canonical GSK-3 substrates, confirming conserved catalytic identity.

   Evidence In vitro kinase assay with recombinant protein against GS-1 peptide, glycogen synthase, axin, and tau

   PMID:15023360

   Open questions at the time

   • No physiological parasite substrate identified at this stage
   • Substrate range shown in vitro does not establish in vivo targets
2. 2004 Medium

   Whether the parasite enzyme behaves like mammalian GSK-3beta mattered for both biology and drug targeting; a binding assay showed PfGSK-3beta does not bind axin, and stage-specific analysis placed the protein in the erythrocyte cytoplasm at the trophozoite stage.

   Evidence Pulldown/binding assay for axin; western blot across stages and immunofluorescence localization

   PMID:15023360

   Open questions at the time

   • Function of vesicle-like localization unresolved
   • Basis for post-transcriptional stage-specific protein accumulation not defined
3. 2012 Medium

   To exploit the enzyme therapeutically, its druggability relative to the human ortholog was tested; thienopyridine carbonitriles selectively inhibited PfGSK-3beta, attributed to ATP-pocket differences.

   Evidence In vitro kinase inhibition assay with recombinant PfGSK-3beta and comparative structural modeling against human GSK-3beta

   PMID:23214499

   Open questions at the time

   • Selectivity shown biochemically, not confirmed against parasites
   • No co-crystal structure of PfGSK-3beta with inhibitor
4. 2016 High

   A physiological substrate and pathway context were unknown; reconstitution showed PfGSK-3beta phosphorylates AMA1 T613 only after PKA priming at S610, defining a hierarchical phosphorylation event required for invasion.

   Evidence Sequential in vitro kinase assays with defined substrates, mutagenesis, and functional erythrocyte invasion assays

   PMID:27698395

   Open questions at the time

   • Direct evidence that PfGSK-3beta phosphorylates AMA1 in vivo during invasion not established
   • Other physiological substrates unknown
5. 2022 High

   How the enzyme's own activity is controlled was unclear; mapping identified autophosphorylation sites in an unconventional N-terminal extension that drive activating conformational changes.

   Evidence Autophosphorylation site mapping combined with SAXS and molecular modeling

   PMID:35023554

   Open questions at the time

   • Upstream trigger for autophosphorylation not identified
   • In vivo relevance of the conformational switch not tested
6. 2022 High

   The essentiality and stage-specific requirement were resolved genetically; disruption spares asexual proliferation but reduces invasion ~69% and, via conditional inactivation, blocks gametocyte maturation.

   Evidence Targeted gene disruption with wildtype and catalytic-mutant rescue, growth/invasion assays, and conditional inactivation during gametocytogenesis with morphological analysis

   PMID:35961464

   Open questions at the time

   • Molecular substrates underlying the gametocyte maturation defect not identified
   • Whether the second PfGSK3 copy has any compensatory role remains untested beyond transcription

• The full physiological substrate repertoire and the signaling inputs that control PfGSK-3beta activity during invasion and gametocytogenesis remain undefined.
• No unbiased in vivo phosphoproteomic substrate map
• Link between vesicular localization and invasion function unresolved
• Mechanism connecting kinase activity to gametocyte morphology unknown